Stoke Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Stoke Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings
Investors are testing whether Stoke Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Investors are testing whether Stoke Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Investors are testing whether Stoke Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest STOK filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Stoke Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →